Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1972 6
1973 8
1974 2
1975 11
1976 6
1977 7
1978 7
1979 3
1980 7
1981 3
1982 1
1983 1
1984 1
1986 3
1987 4
1988 3
1989 1
1990 4
1991 1
1992 1
1995 1
1998 1
1999 2
2000 2
2001 2
2002 2
2005 1
2009 1
2015 3
2017 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Andtbacka RH, et al. Among authors: spitler le. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014293 Clinical Trial.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O. Ott PA, et al. Among authors: spitler le. Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28. Cancer. 2019. PMID: 30690710 Free article. Clinical Trial.
Levamisole.
Spitler LE. Spitler LE. Cutis. 1977 Jun;19(6):719, 728-32. Cutis. 1977. PMID: 872616 No abstract available.
Transfer factor.
Spitler LE. Spitler LE. Int J Dermatol. 1978 Jul-Aug;17(6):445-58. doi: 10.1111/j.1365-4362.1978.tb06179.x. Int J Dermatol. 1978. PMID: 355164 Review. No abstract available.
Malignant melanoma.
Spitler LE. Spitler LE. J Invest Dermatol. 1976 Sep;67(3):435-41. doi: 10.1111/1523-1747.ep12514727. J Invest Dermatol. 1976. PMID: 787436 Free article. Review.
Adjuvant therapy of melanoma.
Spitler LE. Spitler LE. Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):40-8. Oncology (Williston Park). 2002. PMID: 11829281 Free article. Review.
BCG, levamisole and transfer factor in the treatment of cancer.
Spitler LE. Spitler LE. Prog Exp Tumor Res. 1980;25:178-92. doi: 10.1159/000403181. Prog Exp Tumor Res. 1980. PMID: 6986631 Review. No abstract available.
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Spitler LE, Boasberg P, O'Day S, Hamid O, Cruickshank S, Mesko S, Weber RW. Spitler LE, et al. Am J Clin Oncol. 2015 Feb;38(1):61-7. doi: 10.1097/COC.0b013e318287bbae. Am J Clin Oncol. 2015. PMID: 25616203 Clinical Trial.
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. Kwek SS, et al. Among authors: spitler le. Oncoimmunology. 2015 Oct 29;5(4):e1101204. doi: 10.1080/2162402X.2015.1101204. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141383 Free PMC article.
Noninterferon-based adjuvant therapy for high-risk melanoma.
Spitler LE. Spitler LE. Expert Rev Anticancer Ther. 2002 Oct;2(5):547-62. doi: 10.1586/14737140.2.5.547. Expert Rev Anticancer Ther. 2002. PMID: 12382523 Review.
100 results
Jump to page
Feedback